Edition:
India

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran


Friday, 17 Nov 2017 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​. 

Company Quote

1.91
-0.09 -4.50%
24 May 2019